Creso Pharma (ASX:CPH | OTC:COPHF) has announced plans to acquire psychedelic company Halucenex Life Sciences.
Halucenex is focused on researching, developing and licensing novel psychedelic molecules for the global pharmaceutical markets and is currently progressing clinical trials to research the efficacy of psilocybin used in psychedelic-assisted psychotherapy to treat and alleviate Treatment Resistant Depression and other mental illnesses.
Acquisition marks the first 100%-owned psychedelic medicines company on the Australian Stock Exchange.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |